Haemonetics Shares Rise as CSL Plans Full U.S. Plasma Device Switch by 2027
CSL now expects to switch all current U.S. plasma centers to Haemonetics devices by the end of 2027. Guidance is unchanged.
/ 2 items
CSL now expects to switch all current U.S. plasma centers to Haemonetics devices by the end of 2027. Guidance is unchanged.
Haemonetics enters a non-exclusive supply deal with CSL Plasma for NexSys PCS devices with Persona PLUS technology and disposables in the U.S.